Open AccessCD133 inhibition via autophagic degradation in pemetrexed-resistant lung cancer cells by GMI, a fungal immunomodulatory protein from Ganoderma microsporum
Author(s) -
I. Hsin,
LingYen Chiu,
ChuChyn Ou,
Wenjun Wu,
GwoTarng Sheu,
JiunnLiang Ko
Publication year - 2020
Publication title -
british journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.833
H-Index - 236
eISSN - 1532-1827
pISSN - 0007-0920
DOI - 10.1038/s41416-020-0885-8
Subject(s) - cancer research , autophagy , cancer cell , clonogenic assay , viability assay , cancer stem cell , lung cancer , a549 cell , homeobox protein nanog , pemetrexed , cd44 , cancer , biology , apoptosis , medicine , cell , pathology , cisplatin , chemotherapy , biochemistry , genetics , embryonic stem cell , induced pluripotent stem cell , gene
Adaptive drug resistance is an unfavourable prognostic factor in cancer therapy. Pemetrexed-resistant lung cancer cells possess high-metastatic ability via ERK-ZEB1 pathway-activated epithelial-mesenchymal transition. GMI is a fungal immunomodulatory protein that suppresses the survival of several cancer cells.